Invariant natural killer T (iNKT) cell therapies leverage both adaptive and innate immune systems. Our investigational allogeneic iNKT cell therapy candidates directly attack tumor cells via TCR and NK-receptor mediated mechanisms, unlike other cell types such as CAR-T, TCR-T or NK cells.

AGENT-797

Clinical development in:

- Phase 1 multiple myeloma
- Phase 1 solid tumors AGENT-797 +/- checkpoint antibodies

Our lead candidate in oncology, AGENT-797, is in Phase 1 development in multiple myeloma and solid tumors. Clinical readouts expected this year.

We are developing both Native iNKT and Engineered iNKT programs, with a near-term focus on native iNKT cell therapies followed by next-generation engineered iNKT cells with CARs and bispecific cell-engagers. Our pipeline of iNKT cell therapies in oncology is specifically designed for use in combination with validated immuno-oncology therapies, such as checkpoint inhibitors.

iNKT Anti-Cancer Benefit Through:

Tumor lysis via TCR dependent and independent mechanisms
- CD1d ligands through the TCR
- Stress-signals through activating NK receptors, NKG2D, DNAM1
Counteracting myeloid suppressor cells
Recruiting & activating NK & T cells in tumors
Cytokine secretion (e.g. IFNg, IL-4)